Skip to main content

Table 1 Patients baseline characteristic information

From: Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn’s disease: a Chinese real-world study

Index Cohort (n = 19)
Age, y, mean ± SD 29.1 ± 9.1
Male, n (%) 11 (57.9)
Montreal classification, n (%)
Age at diagnosis
  < 16 0 (0)
 16–40 17 (89.5)
  > 40 2 (10.5)
Behavior
 B1 1052.6)
 B2 5 (26.3)
 B3 4 (21.1)
Location
 L1 2 (10.5)
 L2 1 (5.3)
 L3 16 (84.2)
 L4 0 (0)
Disease duration, y, mean ± SD 5.5 ± 4.7
BMI at diagnosis, mean ± SD 19.5 ± 2.4
EIM, n (%) 1 (5.3)
Perianal disease, n (%) 10 (52.6)
Previous biologics exposure, n (%) 17 (89.5)
 1 15 (78.9)
 2 1 (5.3)
 3 0 (0)
 4 1 (5.3)
Intestinal surgeries, n (%) 8 (42.1)
Concomitant drugs, n (%)
 Corticosteroid 1 (5.3)
 Thiopurine 1 (5.3)
UST administration interval, n (%)
 Q12w 14 (73.7)
 Q8w 5 (26.3)